Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
02.06. | H.C. Wainwright stuft Adlai Nortye nach Studienergebnissen herab | 1 | Investing.com Deutsch | ||
02.06. | H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS | 1 | Investing.com | ||
30.05. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
ADLAI NORTYE Aktie jetzt für 0€ handeln | |||||
30.04. | Adlai Nortye Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
14.02. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
08.08.24 | Adlai Nortye Ltd.: Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress | 458 | GlobeNewswire (Europe) | SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,885 | -0,28 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 47,005 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
VERA THERAPEUTICS | 23,560 | +4,34 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
ARTELO BIOSCIENCES | 13,180 | 0,00 % | Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain | First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30... ► Artikel lesen | |
EVOTEC | 7,204 | +0,92 % | Übernahmefantasie angeheizt: Evotec: Neue Hoffnung in der Nierenforschung befeuert Kurs | © Foto: Christian Charisius - dpaDas Hamburger Biotech-Schmiede beteiligt sich an einer großangelegten Studie zu Nierenversagen. Das könnte Evotec völlig neue Marktchancen bescheren.Evotec hat eine... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 42,050 | -2,21 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
ADMA BIOLOGICS | 18,190 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
NURIX THERAPEUTICS | 11,390 | -2,15 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,050 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
TANGO THERAPEUTICS | 5,120 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
APOGEE THERAPEUTICS | 43,490 | +0,25 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
MODERNA | 23,810 | +2,17 % | Moderna-Aktie gewinnt 4,07 Prozent (23,0094 €) | Im US-amerikanischen Wertpapierhandel notiert die Moderna-Aktie derzeit etwas fester. Die Aktie kostete zuletzt 26,73 US-Dollar. An der Börse liegt die Aktie von Moderna gegenwärtig im Plus. Das Papier... ► Artikel lesen | |
CELCUITY | 13,350 | 0,00 % | Celcuity Inc.: Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib | • In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progression... ► Artikel lesen | |
VOR BIOPHARMA | 1,610 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,250 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen |